Addex Therapeutics Ltd.
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
ADXN | SW
Overview
Corporate Details
- ISIN(s):
- CH0029850754 (+2 more)
- LEI:
- 89450068Y9KVP2MQGH86
- Country:
- Switzerland
- Address:
- c/o Addex Pharma SA, Chemin des Aulx 12, 1228 Plan-Les-Ouates
- Sector:
- Manufacturing
Description
Addex Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, orally available small molecule drugs. The company specializes in an emerging class of therapeutics known as allosteric modulators. Its development pipeline targets neurological disorders and other central nervous system (CNS) diseases with significant unmet medical needs, leveraging its proprietary drug discovery platform.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-11-08 01:00 |
Addex Regains Nasdaq Listing Compliance
|
English | 5.2 KB | ||
| 2023-11-02 01:00 |
Addex Announces Participation in the Bio-Europe 2023 Conference
|
English | 5.5 KB | ||
| 2023-10-20 02:00 |
Addex Completes ADS Ratio Change
|
English | 6.5 KB | ||
| 2023-10-06 02:00 |
Addex Announces Plan to Implement ADS Ratio Change
|
English | 7.1 KB | ||
| 2023-09-20 02:00 |
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
|
English | 9.9 KB | ||
| 2023-09-06 02:00 |
Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investm…
|
English | 6.1 KB | ||
| 2023-09-05 02:00 |
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
|
English | 9.3 KB | ||
| 2023-09-04 02:00 |
Addex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Publ…
|
English | 8.2 KB | ||
| 2023-08-10 02:00 |
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides …
|
English | 15.8 KB | ||
| 2023-08-04 02:00 |
Addex Therapeutics to Release Half-Year 2023 Financial Results and Host Confere…
|
English | 6.5 KB | ||
| 2023-08-03 02:00 |
Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 …
|
English | 7.2 KB | ||
| 2023-07-24 02:00 |
Addex mGlu2PAM Demonstrates Potential in Substance Use Disorder
|
English | 9.4 KB | ||
| 2023-06-15 02:00 |
Addex Increases Issued Share Capital to Create Treasury Shares
|
English | 6.4 KB | ||
| 2023-06-01 02:00 |
Addex Shareholders Approve All Resolutions at Annual General Meeting
|
English | 7.3 KB | ||
| 2023-05-18 02:00 |
Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
|
English | 6.3 KB |
Automate Your Workflow. Get a real-time feed of all Addex Therapeutics Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Addex Therapeutics Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Addex Therapeutics Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-27 | N/A | Executive member | Buy | None | 301,345.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 53,760.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 45,450.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 44,856.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 24,423.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 5,487.00 CHF |
| 2023-11-27 | N/A | Non-Executive member | Buy | None | 3,927.00 CHF |
| 2023-11-27 | N/A | Executive member | Buy | None | 2,150.00 CHF |
Peer Companies
